Barclays Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA - Free Report) had its price target trimmed by Barclays from $55.00 to $26.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

NTLA has been the subject of a number of other reports. Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday. Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday. Finally, William Blair reaffirmed a "neutral" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.12.

Intellia Therapeutics Stock Down 6.3 %

Shares of NASDAQ NTLA traded down $0.64 during mid-day trading on Friday, hitting $9.45. 2,998,270 shares of the company traded hands, compared to its average volume of 3,289,680. Intellia Therapeutics has a 1 year low of $8.96 and a 1 year high of $33.28. The stock has a market capitalization of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80. The business has a 50 day moving average of $10.85 and a two-hundred day moving average of $15.55.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 29,000 shares of company stock valued at $352,551. Insiders own 3.20% of the company's stock.

Institutional Trading of Intellia Therapeutics

Several large investors have recently made changes to their positions in NTLA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock worth $77,000 after purchasing an additional 794 shares during the last quarter. Capstone Investment Advisors LLC lifted its stake in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company's stock worth $1,256,000 after buying an additional 831 shares during the last quarter. KBC Group NV boosted its holdings in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock worth $77,000 after buying an additional 1,020 shares during the period. Axxcess Wealth Management LLC boosted its holdings in shares of Intellia Therapeutics by 5.4% during the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company's stock worth $415,000 after buying an additional 1,044 shares during the period. Finally, Ensign Peak Advisors Inc grew its stake in Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after buying an additional 1,100 shares during the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.